Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06361875 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above
A Phase 1 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 910
- Enrollment target
NCT06361875 is a Phase 1 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 910 participants.
The verdict
NCT06361875, a Phase 1 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 910 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different formulations of Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) (MRT5421, MRT5424, and MRT5429) compared to an active control (QIV- standard dose (SD), QIV- high dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.
Interventions
- BIOLOGICAL Quadrivalent Influenza Standard Dose Vaccine
- BIOLOGICAL Quadrivalent Influenza High-Dose Vaccine
- BIOLOGICAL Quadrivalent Influenza mRNA Vaccine MRT5421
- BIOLOGICAL Quadrivalent Influenza mRNA Vaccine MRT5424
- BIOLOGICAL Quadrivalent Influenza mRNA Vaccine MRT5429
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 910 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2025-06-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06361875
The ClinicalTrials.gov registry entry for NCT06361875 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 910 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Quadrivalent Influenza Standard Dose Vaccine is the first listed.
NCT06361875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06361875 about?
NCT06361875 is a clinical study titled "A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above". The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different formulations of Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) (MRT5421, MRT5424, and MRT5429) compared to an active control (QIV- standard dose (SD), ...
What is the current status of trial NCT06361875?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 910 participants. The study started on 2024-04-01. Estimated completion is 2025-06-09.
What interventions are being tested in trial NCT06361875?
The interventions under investigation include: Quadrivalent Influenza Standard Dose Vaccine (BIOLOGICAL), Quadrivalent Influenza High-Dose Vaccine (BIOLOGICAL), Quadrivalent Influenza mRNA Vaccine MRT5421 (BIOLOGICAL), Quadrivalent Influenza mRNA Vaccine MRT5424 (BIOLOGICAL), Quadrivalent Influenza mRNA Vaccine MRT5429 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06361875?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.